All data are based on the daily closing price as of April 2, 2025
a

Alar Pharmaceuticals

6785.TWO
4.54 USD
-0.03
-0.66%

Overview

Last close
4.54 usd
Market cap
303.40M usd
52 week high
14.52 usd
52 week low
3.82 usd
Target price
8.84 usd

Valuation

P/E
20.9929
Forward P/E
N/A
Price/Sales
20.8447
Price/Book Value
4.0616
Enterprise Value
231.59M usd
EV/Revenue
16.0156
EV/EBITDA
17.869

Key financials

Revenue TTM
14.46M usd
Gross Profit TTM
14.40M usd
EBITDA TTM
11.84M usd
Earnings per Share
0.21 usd
Dividend
0.05 usd
Total assets
78.46M usd
Net debt
-20.81M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
  • Symbol
    6785.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Dr. Yung-Shun Wen Ph.D.
  • Headquarter
    Taichung
  • Web site
    https://www.alarpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top